U.S. Entertainment Stock News

NasdaqGS:VRNT
NasdaqGS:VRNTSoftware

Assessing Verint Systems (VRNT) Valuation After New TrustRadius Buyer’s Choice Awards Recognition

TrustRadius awards put Verint Systems (VRNT) in focus Verint Systems (VRNT) recently picked up two TrustRadius 2026 Buyer’s Choice awards, including recognition in the Contact Center category. The awards have brought fresh attention to how its AI powered customer experience tools might relate to the stock. See our latest analysis for Verint Systems. Despite the TrustRadius recognition, Verint Systems’ share price return has been weak over the year, with a year to date share price return...
NasdaqCM:BYRN
NasdaqCM:BYRNAerospace & Defense

Is Byrna Technologies (BYRN) Pricing In Too Much Pessimism After A 35% One-Year Decline?

If you are wondering whether Byrna Technologies at around US$17.50 is a bargain or already pricing in a lot of optimism, you are in the right place. The stock has been through a mixed patch, with a 1.4% gain over the last week, an 11.0% decline over the past month, a 4.7% gain year to date, a 35.3% decline over the past year, and a 94.4% gain over three years that leaves the five year return at 25.0%. These swings have kept Byrna Technologies on the radar of investors watching how sentiment...
NYSE:HIPO
NYSE:HIPOInsurance

Discovering Hidden Opportunities in US Stocks

As the Dow Jones and S&P 500 reach new all-time highs, the U.S. stock market continues to capture investors' attention amidst mixed economic signals, including a weakening labor market and geopolitical developments. In this dynamic environment, identifying promising small-cap stocks can offer valuable opportunities for growth, particularly when these companies demonstrate resilience and potential in sectors poised for expansion.
NasdaqCM:DCTH
NasdaqCM:DCTHMedical Equipment

A Look At Delcath Systems (DCTH) Valuation After New Phase 3 FOCUS Subgroup Data On HEPZATO KIT

Delcath Systems (DCTH) is back in focus after publishing detailed subgroup analyses from its phase 3 FOCUS study on HEPZATO KIT in unresectable metastatic uveal melanoma, helping refine how clinicians view efficacy and safety across different patient groups. See our latest analysis for Delcath Systems. The publication arrives after a mixed stretch for Delcath Systems, with a 30 day share price return of 6.85% and a 90 day share price return decline of 5.86%. The 3 year total shareholder...